POverview
Pulse Biosciences uses Nanosecond Pulsed-Field Ablation (nsPFA) to ablate diseased cells with ultra-short electrical pulses while preserving surrounding tissue. Its CellFX System includes percutaneous and surgical tools, such as a soft tissue ablation electrode, a cardiac clamp, and a 360° cardiac catheter for AFib and other procedures. The company differentiates itself by focusing on high-value surgical applications in cardiology and soft tissue, aiming for precise, non-thermal tissue removal with less collateral damage. Its goal is to make the CellFX System a standard of care in bioelectric medicine and to grow in specialty surgical markets.
Work here?Claim your company
About Pulse Biosciences
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Miami, FL
Founded
2014
Get referred to Pulse Biosciences
See people who can refer or advise you
Simplify's take
What believers are saying
- November 5, 2026 results showed $189.2 million cash and two-year runway.
- Pulse plans Q3 2027 catheter data, Q4 2027 CE Mark, and early-2028 launch.
- Clayman Thyroid Center partnership began commercial thyroid use and real-world evidence collection.
What critics are saying
- Q3 2026 loss widened to $23.1 million while spending rises 15% to 25%.
- Microsecond PFA giants Boston Scientific and Medtronic can outspend Pulse before 2028.
- A failed 2027 AFib readout would crush the platform thesis and force dilutive financing.
What makes Pulse Biosciences unique
- nsPFA uses nanosecond pulses to ablate cells while sparing surrounding tissue structures.
- NANOPULSE-AF enrolled 169 evaluable patients at 15 sites in under six months.
- Robert Duggan still anchors financing and strategy, giving Pulse unusually patient capital.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$443.3M
Above
Industry Average
Funded Over
11 Rounds
Benefits
- Health Insurance
- 401(k) Retirement Plan
- Stock Options
- Employee Stock Purchase Plan
- Flexible Work Hours
- Paid Time Off
- Paid Holidays
- Wellness Program
- Gym Membership
- Family Planning Benefits
- Fertility Treatment Support
- Conference Attendance Budget
Stock Price
Growth & Insights and Company News
6 month growth
-2%1 year growth
3%2 year growth
8%What Pulse Biosciences (PLSE) said on its Q3 earnings call. Pulse Biosciences (NASDAQ:PLSE) said it completed enrollment ahead of schedule in the pivotal U.S. study of its nPulse Cardiac Catheter, setting up a data readout expected in the third quarter of 2027 as the company increases spending on clinical development and launch preparations. On its Nov. 5 third-quarter earnings call, the company reported revenue of $395,000, up from $86,000 a year earlier, while its net loss widened to $23.1 million from $19.4 million. Cash and marketable securities totaled $189.2 million at Sept. 30, which CEO Paul LaViolette said provides approximately two years of runway. Pulse Biosciences is developing devices based on its nanosecond pulsed field ablation, or nsPFA, technology for applications including atrial fibrillation and thyroid disease. Its cardiac catheter is designed to isolate pulmonary veins, a common target in atrial fibrillation ablation. Cardiac catheter study moves into follow-up. The NANOPULSE-AF study reached its enrollment target in early October, completing the process in less than six months, about three months ahead of the original schedule. The study enrolled 169 evaluable patients and 20 roll-in patients across 15 sites, LaViolette said. All patients are now in follow-up. The study's efficacy endpoint measures freedom from treatment failure through 12 months, using a combination of six- and 12-month follow-up data. Pulse expects final patient data in the third quarter of 2027 and plans to incorporate the results into the final clinical module of its U.S. premarket approval submission. LaViolette said the company has begun modular regulatory submissions and expects a European CE Mark for the catheter in the fourth quarter of 2027. It is preparing to support a launch beginning in early 2028. The company also plans to submit an investigational device exemption application in the fourth quarter of 2026 for a study in persistent atrial fibrillation. Its existing pivotal trial focuses on paroxysmal, or intermittent, atrial fibrillation. In Europe, the company's feasibility study has enrolled more than 190 patients, including more than 155 in a five-second ablation cohort. Pulse plans to submit data for presentation at the AF Symposium in early 2027, including more than 100 patients with 12-month follow-up. Earlier results presented in April covered 53 patients in the five-second cohort with one-year follow-up. Freedom from atrial fibrillation measured by a 24-hour Holter monitor was 96%, while estimated freedom from recurrent atrial fibrillation, flutter or tachycardia was 90%. LaViolette said the European data could help inform expectations for the U.S. trial, although the company has not released the pivotal study's results. Manufacturing and partnership planning. Pulse is preparing to increase manufacturing capacity for the catheter and its console. LaViolette said the company uses more than one contract manufacturer for catheter supply and plans to manufacture consoles internally. It is also working on training, mapping-system integration and customer segmentation. The preparations are intended to support either a direct launch or a partnership. Co-Chair Bob Duggan said a partnership with a larger company could help Pulse gain market share, but potential partners are looking for additional evidence. He said terms would be addressed later as appropriate. Asked about safety, LaViolette said patients in the U.S. pivotal study received fluids before their procedures as a step to mitigate hemolysis, or red blood cell breakdown. He declined to disclose specific pivotal-study safety data. He also said the company plans a clinical comparison using biomarkers to investigate differences between nanosecond and microsecond PFA, without taking tissue samples from patients. Surgical and thyroid programs advance. Pulse continues to enroll patients in NANOCLAMP-AF, a study of its surgical clamp for treating atrial fibrillation during cardiac surgery. LaViolette said the company remains on track to finish enrollment by the end of the first half of 2027 and expects a CE Mark for the clamp in the fourth quarter of that year. The company also completed enrollment in its PRECISE-BTN study of Vybrance for symptomatic benign thyroid nodules. The study enrolled 100 patients, twice its original design. Preliminary data presented at the American Thyroid Association showed that 86% of patients achieved the primary endpoint of a greater than 50% reduction in nodule volume after a single treatment, LaViolette said. He also reported an average 78% improvement in the overall quality-of-life score at six months and no serious adverse events. Additional results are expected in 2027 as patients complete follow-up. Pulse plans to use the study data to support a 510(k) submission for an on-label benign thyroid nodule indication. The Vybrance percutaneous electrode already has FDA clearance, according to the company. Spending expected to rise. CFO Jon Skinner said third-quarter GAAP costs and expenses increased to $24.7 million from $20.5 million a year earlier, driven primarily by clinical investments and employee-related spending. The non-GAAP net loss rose to $17.5 million from $13.5 million. Pulse raised $95.8 million through its at-the-market equity program during the quarter and more than $150 million in net proceeds since May. Skinner said approximately $64 million of capacity remained under the program, with cumulative 2026 dilution of less than 6%. Operating cash use was $15.3 million in the third quarter, down from $18.7 million in the second quarter, primarily because of the timing of clinical-study payments. Skinner expects quarterly non-GAAP costs and expenses in coming quarters to run 15% to 25% above the approximately $20 million average for the second and third quarters, as Pulse funds further studies, manufacturing and pre-commercial work. About Pulse Biosciences (NASDAQ:PLSE). Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue. The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.
Pulse Biosciences finished enrolment in its pivotal US study of the nPulse Cardiac Catheter about three months early. Data is expected in the third quarter of 2027, and the company plans a European CE Mark that quarter, with a launch from early 2028. The study enrolled 169 evaluable patients across 15 sites. Pulse has begun modular regulatory submissions. Third-quarter revenue was $395,000, up from $86,000 a year earlier. The net loss widened to $23.1 million from $19.4 million. Cash and marketable securities totalled $189.2 million at September 30, which chief executive officer Paul LaViolette said gives about two years of runway. Pulse raised $95.8 million through its at-the-market equity programme in the quarter. The chief financial officer expects quarterly non-GAAP costs to run 15% to 25% above the roughly $20 million average of the prior two quarters.
Pulse Biosciences (NASDAQ:PLSE) price target raised to $64.00. Pulse Biosciences (NASDAQ:PLSE - Get Free Report) had its price objective upped by equities researchers at Needham & Company LLC from $58.00 to $64.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's target price indicates a potential upside of 20.60% from the stock's current price. A number of other research analysts have also issued reports on PLSE. BTIG Research started coverage on Pulse Biosciences in a report on Wednesday, September 23rd. They issued a "buy" rating and a $70.00 target price for the company. Oppenheimer upped their price target on Pulse Biosciences from $35.00 to $60.00 and gave the stock an "outperform" rating in a report on Tuesday, October 13th. Canaccord Genuity Group raised their price target on Pulse Biosciences from $43.00 to $58.00 and gave the company a "buy" rating in a research note on Tuesday, October 6th. Mizuho set a $55.00 price objective on Pulse Biosciences in a report on Tuesday, October 13th. Finally, Freedom Capital upgraded Pulse Biosciences to a "strong-buy" rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $61.40. Pulse Biosciences stock down 7.0%. Shares of PLSE opened at $53.07 on Friday. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $58.90. The firm's 50 day moving average price is $51.45 and its 200 day moving average price is $32.08. Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.01). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.52 million. During the same quarter last year, the company earned ($0.29) earnings per share. Pulse Biosciences's quarterly revenue was down 54.1% compared to the same quarter last year. On average, equities research analysts forecast that Pulse Biosciences will post -1.34 EPS for the current fiscal year. Insider buying and selling at Pulse Biosciences. In other news, COO Liane Teplitsky acquired 1,001 shares of the firm's stock in a transaction dated Tuesday, September 1st. The stock was acquired at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer owned 4,095 shares of the company's stock, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 4,095 shares of company stock valued at $199,931 over the last three months. 74.00% of the stock is currently owned by corporate insiders. Institutional trading of Pulse Biosciences. Several institutional investors and hedge funds have recently bought and sold shares of the business. Osterweis Capital Management Inc. acquired a new stake in Pulse Biosciences during the 2nd quarter worth $28,000. Sterling Capital Management LLC increased its stake in Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company's stock valued at $31,000 after purchasing an additional 549 shares during the period. Jupiter Topco LLC acquired a new position in Pulse Biosciences in the second quarter valued at $241,000. Axxcess Wealth Management LLC acquired a new position in Pulse Biosciences in the third quarter valued at $242,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Pulse Biosciences in the second quarter valued at about $290,000. Hedge funds and other institutional investors own 76.95% of the company's stock. Pulse Biosciences company profile. Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue. The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions. Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Pulse Biosciences (PLSE) set to post quarterly earnings on Thursday. October 29, 2026 Pulse Biosciences (NASDAQ:PLSE - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Pulse Biosciences to post earnings of ($0.3095) per share and revenue of $0.52 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET. Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. On average, analysts expect Pulse Biosciences to post ($1.34) EPS for the current fiscal year and ($1.41) EPS for the next fiscal year. Pulse Biosciences price performance. NASDAQ:PLSE opened at $53.67 on Thursday. The business has a fifty day simple moving average of $50.82 and a two-hundred day simple moving average of $30.89. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90. The company has a market capitalization of $3.80 billion, a P/E ratio of -45.48 and a beta of 1.57. Analyst upgrades and downgrades. A number of analysts recently weighed in on PLSE shares. Wall Street Zen upgraded Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, September 6th. Oppenheimer boosted their price objective on shares of Pulse Biosciences from $35.00 to $60.00 and gave the company an "outperform" rating in a research report on Tuesday, October 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. Freedom Capital upgraded shares of Pulse Biosciences to a "strong-buy" rating in a report on Wednesday, September 9th. Finally, Canaccord Genuity Group raised their target price on Pulse Biosciences from $43.00 to $58.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.20. Discover more MarketBeat All Access MarketBeat Research Tools Insider buying and selling. In other news, COO Liane Teplitsky acquired 1,001 shares of Pulse Biosciences stock in a transaction on Tuesday, September 1st. The stock was acquired at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have bought 4,095 shares of company stock worth $199,931. Corporate insiders own 74.00% of the company's stock. About Pulse Biosciences. Pulse Biosciences, Inc NASDAQ: PLSE is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue. The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Pulse Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list. While Pulse Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat
Pulse Biosciences (NASDAQ:PLSE) stock jumps 6.2% - still a Buy? October 19, 2026 Key points. * Pulse Biosciences shares rose 6.2% to about $47.18, although trading volume was 64% below the average daily level. The stock has a $3.34 billion market capitalization and trades below its 50-day moving average of $49.82. * Analyst sentiment is broadly positive, with a consensus rating of "Moderate Buy" and an average price target of $60.20. Recent targets range from $58 to $70, though Weiss Ratings maintained a sell rating. * The company continues to report weak financial results, including a quarterly loss of $0.36 per share versus the expected $0.29 loss and revenue of $0.43 million versus the $0.53 million estimate. Pulse Biosciences is developing Nano-Pulse Stimulation technology, including its CellFX dermatology system. * MarketBeat All Access makes it easier to follow Pulse Biosciences with alerts, analyst ratings, and deeper research - now $149 a year with your rate locked in. Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) shares were up 6.2% during mid-day trading on Monday. The stock traded as high as $47.61 and last traded at $47.1770. Approximately 139,102 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 390,397 shares. The stock had previously closed at $44.43. Analyst ratings changes. A number of equities analysts have commented on the stock. BTIG Research started coverage on shares of Pulse Biosciences in a research report on Wednesday, September 23rd. They set a "buy" rating and a $70.00 price objective for the company. Wall Street Zen upgraded shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday, September 6th. Canaccord Genuity Group boosted their price target on shares of Pulse Biosciences from $43.00 to $58.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a "buy" rating and a $58.00 price objective for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $60.20. Pulse Biosciences trading up 6.1%. The stock's 50 day moving average price is $49.82 and its two-hundred day moving average price is $34.43. The firm has a market capitalization of $3.34 billion, a price-to-earnings ratio of -39.95 and a beta of 1.57. Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. On average, sell-side analysts forecast that Pulse Biosciences, Inc will post -1.34 earnings per share for the current fiscal year. Insider activity at Pulse Biosciences. In other news, COO Liane Teplitsky purchased 1,001 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer directly owned 4,095 shares in the company, valued at approximately $204,545.25. The trade was a 32.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders purchased 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by insiders. Institutional trading of Pulse Biosciences. A number of institutional investors have recently bought and sold shares of the company. Osterweis Capital Management Inc. purchased a new position in shares of Pulse Biosciences in the second quarter valued at $28,000. Jupiter Topco LLC purchased a new position in Pulse Biosciences during the 2nd quarter valued at about $241,000. GSA Capital Partners LLP acquired a new position in Pulse Biosciences during the second quarter worth about $290,000. Legal & General Group Plc acquired a new position in Pulse Biosciences during the second quarter worth about $395,000. Finally, Cetera Investment Advisers acquired a new position in Pulse Biosciences during the first quarter worth about $387,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors. Pulse Biosciences company profile. Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue. Discover more MarketBeat All Access Research tools subscription Stock Average Calculator The company's lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Pulse Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list. While Pulse Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall. Continue following MarketBeat
Pulse Biosciences is Hiring for 11 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Pulse Biosciences
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Miami, FL
Founded
2014
Pulse Biosciences is Hiring for 11 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs